145 related articles for article (PubMed ID: 37730961)
21. Detailed identification of epidermal growth factor receptor mutations in lung adenocarcinoma: Combining radiomics with machine learning.
Li S; Luo T; Ding C; Huang Q; Guan Z; Zhang H
Med Phys; 2020 Aug; 47(8):3458-3466. PubMed ID: 32416013
[TBL] [Abstract][Full Text] [Related]
22. Value of
Hu Y; Zhao X; Zhang J; Han J; Dai M
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):231-240. PubMed ID: 32588088
[TBL] [Abstract][Full Text] [Related]
23. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma.
Chang C; Zhou S; Yu H; Zhao W; Ge Y; Duan S; Wang R; Qian X; Lei B; Wang L; Liu L; Ruan M; Yan H; Sun X; Xie W
Eur Radiol; 2021 Aug; 31(8):6259-6268. PubMed ID: 33544167
[TBL] [Abstract][Full Text] [Related]
24. Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With
Tang X; Li Y; Yan WF; Qian WL; Pang T; Gong YL; Yang ZG
Front Oncol; 2021; 11():719919. PubMed ID: 34660285
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis of Invasive Lung Adenocarcinoma Based on Chest CT Radiomic Features of Part-Solid Pulmonary Nodules: A Multicenter Study.
Wu G; Woodruff HC; Shen J; Refaee T; Sanduleanu S; Ibrahim A; Leijenaar RTH; Wang R; Xiong J; Bian J; Wu J; Lambin P
Radiology; 2020 Nov; 297(2):451-458. PubMed ID: 32840472
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of first generation EGFR-TKIs and chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations].
Li HX; Wang ZZ; Zhang GW; Zhang MN; Zheng XX; Yang JP; Ma ZY; Wang HJ
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):783-791. PubMed ID: 31648503
[No Abstract] [Full Text] [Related]
27. Role of intratumoral and peritumoral CT radiomics for the prediction of EGFR gene mutation in primary lung cancer.
Yamazaki M; Yagi T; Tominaga M; Minato K; Ishikawa H
Br J Radiol; 2022 Dec; 95(1140):20220374. PubMed ID: 36115683
[TBL] [Abstract][Full Text] [Related]
28. Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.
Xu Z; Hao X; Lin L; Li J; Xing P
Thorac Cancer; 2021 Aug; 12(16):2233-2240. PubMed ID: 34180588
[TBL] [Abstract][Full Text] [Related]
29. A computerized tomography-based radiomic model for assessing the invasiveness of lung adenocarcinoma manifesting as ground-glass opacity nodules.
Zhu M; Yang Z; Wang M; Zhao W; Zhu Q; Shi W; Yu H; Liang Z; Chen L
Respir Res; 2022 Apr; 23(1):96. PubMed ID: 35429974
[TBL] [Abstract][Full Text] [Related]
30. Integrative nomogram of intratumoral, peritumoral, and lymph node radiomic features for prediction of lymph node metastasis in cT1N0M0 lung adenocarcinomas.
Das SK; Fang KW; Xu L; Li B; Zhang X; Yang HF
Sci Rep; 2021 May; 11(1):10829. PubMed ID: 34031529
[TBL] [Abstract][Full Text] [Related]
31. Predicting Ki-67 labeling index level in early-stage lung adenocarcinomas manifesting as ground-glass opacity nodules using intra-nodular and peri-nodular radiomic features.
Zhu M; Yang Z; Zhao W; Wang M; Shi W; Cheng Z; Ye C; Zhu Q; Liu L; Liang Z; Chen L
Cancer Med; 2022 Nov; 11(21):3982-3992. PubMed ID: 35332684
[TBL] [Abstract][Full Text] [Related]
32. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
[TBL] [Abstract][Full Text] [Related]
33. Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors.
Yousefi B; LaRiviere MJ; Cohen EA; Buckingham TH; Yee SS; Black TA; Chien AL; Noël P; Hwang WT; Katz SI; Aggarwal C; Thompson JC; Carpenter EL; Kontos D
Sci Rep; 2021 May; 11(1):9984. PubMed ID: 33976268
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
Wang S; Xie T; Hao X; Wang Y; Hu X; Wang L; Li Y; Li J; Xing P
Thorac Cancer; 2021 Oct; 12(19):2585-2593. PubMed ID: 34490724
[TBL] [Abstract][Full Text] [Related]
35. Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status.
Liu Z; Zhang T; Lin L; Long F; Guo H; Han L
Biomed Eng Online; 2023 Feb; 22(1):17. PubMed ID: 36810090
[TBL] [Abstract][Full Text] [Related]
36. (99m)Tc-3PRGD2 SPECT/CT Imaging for Monitoring Early Response of EGFR-TKIs Therapy in Patients with Advanced-Stage Lung Adenocarcinoma.
Zhang Z; Zhao X; Ding C; Wang J; Zhang J; Wang F
Cancer Biother Radiopharm; 2016 Sep; 31(7):238-45. PubMed ID: 27563805
[TBL] [Abstract][Full Text] [Related]
37. Prediction of pathological nodal involvement by CT-based Radiomic features of the primary tumor in patients with clinically node-negative peripheral lung adenocarcinomas.
Liu Y; Kim J; Balagurunathan Y; Hawkins S; Stringfield O; Schabath MB; Li Q; Qu F; Liu S; Garcia AL; Ye Z; Gillies RJ
Med Phys; 2018 Jun; 45(6):2518-2526. PubMed ID: 29624702
[TBL] [Abstract][Full Text] [Related]
38. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
39. Radiomic Detection of EGFR Mutations in NSCLC.
Rossi G; Barabino E; Fedeli A; Ficarra G; Coco S; Russo A; Adamo V; Buemi F; Zullo L; Dono M; De Luca G; Longo L; Dal Bello MG; Tagliamento M; Alama A; Cittadini G; Pronzato P; Genova C
Cancer Res; 2021 Feb; 81(3):724-731. PubMed ID: 33148663
[TBL] [Abstract][Full Text] [Related]
40. Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result.
Chen Y; Yuan E; Sun G; Song B; Yao J
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
